.png)
.png)
Executive Vice President
Institute for Clinical Pharmacodynamics
Disclosure(s): Adagio Therapeutics: Grant/Research Support; Amplyx Pharmaceuticals, Inc: Grant/Research Support; AN2 Therapeutics: Grant/Research Support; Antabio SAS: Grant/Research Support; Arcutis Biotherapeutics, Inc: Grant/Research Support; B. Braun Medical Inc.: Grant/Research Support; Basilea Pharmaceutica: Grant/Research Support; Boston Pharmaceuticals: Grant/Research Support; Bravos Biosciences: Ownership Interest; Celdara Medical LLC: Grant/Research Support; Cidara Therapeutics Inc: Grant/Research Support; Cipla USA: Grant/Research Support; Crestone Inc: Grant/Research Support; CXC: Grant/Research Support; Debiopharm International SA: Grant/Research Support; Entasis Therapeutics: Grant/Research Support; Evopoint Biosciences Co.: Grant/Research Support; Fedora Pharmaceuticals: Grant/Research Support; GlaxoSmithKline: Grant/Research Support; Hoffmann-La Roche: Grant/Research Support; ICPD: Ownership Interest; ICPD Biosciences, LLC.: Ownership Interest; Insmed Inc.: Grant/Research Support; Iterum Therapeutics Limited: Grant/Research Support; Kaizen Bioscience, Co.: Grant/Research Support; KBP Biosciences USA: Grant/Research Support; Lassen Therapeutics: Grant/Research Support; Matinas Biopharma: Grant/Research Support; Meiji Seika Pharma Co., Ltd.: Grant/Research Support; Melinta Therapeutics: Grant/Research Support; Menarini Ricerche S.p.A: Grant/Research Support; Mutabilis: Grant/Research Support; Nabriva Therapeutics AG: Grant/Research Support; Novartis Pharmaceuticals Corp.: Grant/Research Support; Paratek Pharmaceuticals, Inc.: Grant/Research Support; PureTech Health: Grant/Research Support; Sfunga Therapeutics: Grant/Research Support; Spero Therapeutics,: Grant/Research Support; Suzhou Sinovent Pharmaceuticals Co.: Grant/Research Support; TauRx Therapeutics: Grant/Research Support; Tetraphase Pharmaceuticals: Grant/Research Support; tranScrip Partners: Grant/Research Support; Utility Therapeutics: Grant/Research Support; Valanbio Therapeutics, Inc.: Grant/Research Support; VenatoRx: Grant/Research Support; Wockhardt Bio AG: Grant/Research Support
Dr. Christopher M. Rubino is one of three principal founders and the Executive Vice President, Pharmacometrics at the Institute for Clinical Pharmacodynamics (ICPD). He is also an Adjunct Assistant Research Professor in the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo. Dr. Rubino received his BS in Pharmacy from the University of Connecticut, his PharmD from the University at Buffalo, and completed a two-year post-doctoral fellowship in pediatric pharmacology at the Women’s Hospital of Greensboro.
He has served as a resource for pharmaceutical firms during the submission of adult- and pediatric-related filings to the Food and Drug Administration and European Medicines Agency across several therapeutic areas. His experience in this area spans the full breadth of activities from designing studies in adults and children to analysis of PK-PD data from such studies and, ultimately, to presentation at regulatory and international scientific meetings. He is a member of the International Society of Pharmacometrics and the American Society for Microbiology, and also serves as a member of the Antimicrobial Agents and Chemotherapy Editorial Board. He has authored more than 100 peer-reviewed publications and has assisted in refereeing numerous industry journals, including Diagnostic Microbiology and Infectious Diseases, The Journal of Clinical Pharmacology, and the Journal of Antimicrobial Chemotherapy.